Investor Presentaiton
Innovation: R&D pipeline changes since last quarter
Phase I
+4348413 (GMMA) Gonorrhea
+5251738 (TLR8 agonist) HBV
+4524184 (integrase inhibitor) HIV
+4172239 (DNMTI inhibitor) sickle
cell disease
+3536867 (bivalent conjugate)
Salmonella (Typhoid +
Paratyphoid A)
+XMT-2056 (STING agonist ADC)
cancer (wholly owned by Mersana
Therapeutics)
3915393 (TG2 inhibitor) celiac
disease*
**
Phase II
4406371 (live, attenuated)
MMRVns
4106647 (protein-adjuvant) HPV
BVL-GSK098 (ethionamide
booster) tuberculosis
VIR-2482 (neutralizing
monoclonal antibody) influenza
+ Benlysta (anti-BLYS) Systemic
sclerosis associated interstitial
lung disease
3878858 (bioconjugated,
recombinant protein) S. aureus
Phase III
+ tebipenem pivoxil (antibacterial
carbapenem) CUTI
bepirovirsen (HBV ASO) HBV
Registration
4353001 (Sanofi) COVID-19
Rotarix liquid US (live attenuated,
PCV free) rotavirus
Covifenz (Medicago) COVID-19***
Key
+ Addition to pipeline
Deletion from pipeline due to approval or termination
Progressed to new phase
GSK
* GSK has an exclusive global license option to co-develop and commercialize the candidate
**Asset returned to Research, termination for indication only
33
33View entire presentation